Dr. Luyuan Li earned his medical training in China, followed by an M.S. in Biology from New York University and a Ph.D. in Cancer Biology from the University of Miami Miller School of Medicine. His doctoral and post-doctoral research focused on the IDH pathway in chondrosarcoma pathogenesis and progression, elucidating the mechanisms of IDH deregulation and its crosstalk with signaling pathways such as HIF and integrin in mesenchymal tumors. This work led to several first-author research and review publications, a book chapter, and presentations at major oncology conferences including CTOS, AACR, ASCO, and ASTRO. Notably, his study was the first to demonstrate the anti-tumor activity of a mutant IDH1 inhibitor in chondrosarcoma, contributing to the initiation of a clinical trial evaluating Ivosidenib in patients with advanced disease. In July 2025, Dr. Li joined the Internal Medicine Residency Program at North Alabama Medical Center. With plans to pursue a fellowship in Hematology and Oncology, Dr. Li aims to become a clinician-scientist dedicated to advancing cancer research and improving patient outcomes. His research interests encompass the molecular mechanisms of tumorigenesis, development of targeted and immune-based cancer therapies, integration of genomic profiling for precision oncology, and application of advanced imaging technologies in cancer diagnosis and treatment.